DB:23J

Stock Analysis Report

Executive Summary

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD).


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has ProMIS Neurosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 23J's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.1%

23J

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-28.2%

23J

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 23J underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 23J underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

23JIndustryMarket
7 Day-7.1%-2.3%-0.2%
30 Day-21.2%-3.2%0.3%
90 Day18.2%6.3%3.7%
1 Year-28.2%-28.2%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is ProMIS Neurosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ProMIS Neurosciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether ProMIS Neurosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ProMIS Neurosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 23J’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through ProMIS Neurosciences regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is ProMIS Neurosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-36.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 23J is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 23J is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 23J is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 23J is forecast to have no revenue next year.

High Growth Revenue: 23J is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 23J's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ProMIS Neurosciences performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 23J is currently unprofitable.

Growing Profit Margin: 23J is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 23J is unprofitable, and losses have increased over the past 5 years at a rate of -35.2% per year.

Accelerating Growth: Unable to compare 23J's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 23J is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 23J's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ProMIS Neurosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 23J has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 23J has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 23J is debt free.

Reducing Debt: 23J's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 23J has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 23J's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 23J has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 23J has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35% each year


Next Steps

Dividend

What is ProMIS Neurosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 23J's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 23J's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 23J's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 23J's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 23J's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Elliot Goldstein (68yo)

4.6yrs

Tenure

CA$883,661

Compensation

Dr. Elliot Goldstein, M.D. has been the Chief Executive Officer and President of ProMIS Neurosciences Inc. (Alternate name -Amorfix Life Sciences Ltd.) since July 2015 respectively. Dr. Goldstein is a Co-F ...


CEO Compensation Analysis

Compensation vs Market: Elliot's total compensation ($USD666.33K) is above average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Elliot's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Eugene Williams
Executive Chairman4.6yrsCA$883.66k2.83% CA$1.1m
Elliot Goldstein
President4.6yrsCA$883.66k2.61% CA$1.1m
Neil Cashman
Founder0yrsCA$108.00k2.12% CA$855.8k
Daniel Geffken
Chief Financial Officer2.9yrsCA$80.42kno data
Johanne Kaplan
Chief Development Officer3.6yrsCA$310.08k0.10% CA$42.4k
James Kupiec
Chief Medical Officer1.4yrsCA$1.20mno data
Steven Plotkin
Chief Physics Officer4.4yrsno datano data
Ernest Bush
Head of Pharmacology/Toxicology1.8yrsno datano data
Russell Blacher
Head of Manufacturing1.8yrsno datano data

3.3yrs

Average Tenure

62yo

Average Age

Experienced Management: 23J's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eugene Williams
Executive Chairman4.6yrsCA$883.66k2.83% CA$1.1m
Elliot Goldstein
President4.6yrsCA$883.66k2.61% CA$1.1m
Neil Cashman
Founder0yrsCA$108.00k2.12% CA$855.8k
William Wyman
Independent Director5.9yrsno data1.27% CA$514.0k
Anthony Giovinazzo
Independent Director2.9yrsno data0.47% CA$188.5k
William Mobley
Member of Scientific Advisory Board2.7yrsno datano data
Richard Gregory
Independent Director3.3yrsno datano data
Johannes Roth
Independent Director6.2yrsno datano data
Todd Golde
Co-Chair of Scientific Advisory Board0yrsno datano data
Patrick Kirwin
Independent Director4.7yrsno data1.13% CA$454.8k

4.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 23J's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 23J insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.


Top Shareholders

Company Information

ProMIS Neurosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ProMIS Neurosciences, Inc.
  • Ticker: 23J
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$57.836m
  • Listing Market Cap: CA$40.410m
  • Shares outstanding: 275.41m
  • Website: https://www.promisneurosciences.com

Location

  • ProMIS Neurosciences, Inc.
  • 1920 Yonge Street
  • Suite 200
  • Toronto
  • Ontario
  • M4S 3E2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PMNTSX (The Toronto Stock Exchange)YesCommon SharesCACADOct 2005
ARFX.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2005
23JDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2005

Biography

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AßO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:21
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.